| answer text |
<p>The Chief Medical Officer and NHS England issued a letter on the 31 October 2018,
and a supplementary letter on 20 November 2018, providing guidance to clinicians,
the National Health Service and independent organisations following the rescheduling
of cannabis-based products for medicinal use on 1 November 2018. This signposts interim
guidance issued by the Royal College of Physicians, British Paediatric Neurology Association
and Association of British Neurologists.</p><p> </p><p>Furthermore, the National Institute
for Health and Care Excellence (NICE), has been commissioned to develop guidelines
on the prescribing of cannabis-based medicinal products by October 2019. The guidance
will focus on four indications: chronic pain, intractable nausea and vomiting, treatment-resistant
epilepsy and spasticity. It will be based on the best available international evidence
and produced using NICE’s world-renowned process for delivering such guidelines. This
guidance will update and replace the interim guidance.</p><p> </p>
|
|
